Whitehawk Therapeutics (WHWK) Share-based Compensation (2016 - 2026)

Whitehawk Therapeutics (WHWK) has 11 years of Share-based Compensation data on file, last reported at $2.2 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 30.54% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $9.3 million, a 4.68% increase from a year earlier, with the FY2025 full-year figure at $9.9 million, down 8.91% from the prior year.
• Share-based Compensation for Q1 2026 stood at $2.2 million, down from $2.4 million in the prior quarter.
• Over the last five years, Share-based Compensation for WHWK reached as high as $7.9 million in Q3 2025 and fell as low as -$5.5 million in Q4 2022.
• Historically, Share-based Compensation has averaged $2.4 million across 5 years, with a median of $2.7 million in 2023.
• On a YoY basis, Share-based Compensation climbed as much as 5630.77% in 2022 and fell as far as 469.79% in 2022.
• Year by year, Share-based Compensation stood at -$5.5 million in 2022, then jumped by 156.24% to $3.1 million in 2023, then tumbled by 40.41% to $1.9 million in 2024, then gained by 28.8% to $2.4 million in 2025, then declined by 8.17% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $2.2 million in Q1 2026, $2.4 million in Q4 2025, and $7.9 million in Q3 2025.